Replication of SARS-CoV-2 in Cell Lines Used in Public Health Surveillance Programmes with Special Emphasis on Biosafety
Overview
Authors
Affiliations
Background & Objectives: Polio, measles, rubella, influenza and rotavirus surveillance programmes are of great public health importance globally. Virus isolation using cell culture is an integral part of such programmes. Possibility of unintended isolation of SARS-CoV-2 from clinical specimens processed in biosafety level-2 (BSL-2) laboratories during the above-mentioned surveillance programmes, cannot be ruled out. The present study was conducted to assess the susceptibility of different cell lines to SARS-CoV-2 used in these programmes.
Methods: Replication of SARS-CoV-2 was studied in RD and L20B, Vero/hSLAM, MA-104 and Madin-Darby Canine Kidney (MDCK) cell lines, used for the isolation of polio, measles, rubella, rotavirus and influenza viruses, respectively. SARS-CoV-2 at 0.01 multiplicity of infection was inoculated and the viral growth was assessed by observation of cytopathic effects followed by real-time reverse transcription-polymerase chain reaction (qRT-PCR). Vero CCL-81 cell line was used as a positive control.
Results: SARS-CoV-2 replicated in Vero/hSLAM, and MA-104 cells, whereas it did not replicate in L20B, RD and MDCK cells. Vero/hSLAM, and Vero CCL-81 showed rounding, degeneration and detachment of cells; MA-104 cells also showed syncytia formation. In qRT-PCR, Vero/hSLAM and MA-104 showed 10 and Vero CCL-81 showed 10 viral RNA copies per μl. The 50 per cent tissue culture infectious dose titres of Vero/hSLAM, MA-104 and Vero CCL-81 were 10, 10 and 10/ml, respectively.
Interpretation & Conclusions: Replication of SARS-CoV-2 in Vero/hSLAM and MA-104 underscores the possibility of its unintended isolation during surveillance procedures aiming to isolate measles, rubella and rotavirus. This could result in accidental exposure to high titres of SARS-CoV-2, which can result in laboratory acquired infections and community risk, highlighting the need for revisiting biosafety measures in public health laboratories.
Romero-Ramirez A, Somasundaran A, Kontogianni K, Parkes J, Hussain Y, Gould S J Infect. 2025; 90(2):106413.
PMID: 39824291 PMC: 11825380. DOI: 10.1016/j.jinf.2025.106413.
Optimization of SARS-CoV-2 culture from clinical samples for clinical trial applications.
Wooding D, Buist K, Romero-Ramirez A, Savage H, Watkins R, Bengey D mSphere. 2024; 9(11):e0030424.
PMID: 39412283 PMC: 11580409. DOI: 10.1128/msphere.00304-24.
Differential Cell Line Susceptibility to the SARS-CoV-2 Omicron BA.1.1 Variant of Concern.
Dighe H, Sarkale P, Patil D, Mohandas S, Shete A, Sahay R Vaccines (Basel). 2022; 10(11).
PMID: 36423057 PMC: 9696227. DOI: 10.3390/vaccines10111962.
SARS-CoV-2 air and surface contamination in residential settings.
Correia G, Rodrigues L, Afonso M, Mota M, Oliveira J, Soares R Sci Rep. 2022; 12(1):18058.
PMID: 36302823 PMC: 9610309. DOI: 10.1038/s41598-022-22679-y.